Tumor Necrosis Factor Receptor Superfamily Member 18 ? Pipeline Review, H1?2018

Posted by vanshrao on February 7th, 2018

Tumor Necrosis Factor Receptor Superfamily Member 18 Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18 pipeline Target constitutes close to 14 molecules. Out of which approximately 14 molecules are developed by Companies. The latest report Tumor Necrosis Factor Receptor Superfamily Member 18 Pipeline Review, H1 2018, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 18 Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.

Tumor Necrosis Factor Receptor Superfamily Member 18 Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18 Glucocorticoid induced tumor necrosis factor receptor or TNFRSF18 or AITR is a protein encoded by TNFRSF18 gene. TNFSF18 is involved in interactions between activated Tlymphocytes and endothelial cells and in the regulation of Tcell receptormediated cell death. It mediated NFkappaB activation via the TRAF2/NIK pathway. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 6, 4 and 2 respectively. Report covers products from therapy areas Oncology which include indications Solid Tumor, Melanoma, NonSmall Cell Lung Cancer, Adenocarcinoma Of The Gastroesophageal Junction, Blood Cancer, Endometrial Cancer, Esophageal Cancer, Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Lymphoma, Metastatic Melanoma, Metastatic Renal Cell Carcinoma and Transitional Cell Carcinoma Urothelial Cell Carcinoma.

Furthermore, this report also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 18 Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18 targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.

Scope

The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 18 Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18
The report reviews Tumor Necrosis Factor Receptor Superfamily Member 18 Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 18 Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18 targeted therapeutics and enlists all their major and minor projects
The report assesses Tumor Necrosis Factor Receptor Superfamily Member 18 Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 18 Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18 targeted therapeutics

 

For more information, please visit @ https://www.24marketreports.com/life-sciences/tumor-necrosis-factor-receptor-superfamily-member-18-glucocorticoid-induced-tumor-necrosis-factor-receptor-or-activation-inducible-tnfr-family-receptor-or-glucocorticoid-induced-tnfr-related-protein-or-cd357-or-tnfrsf18pipeline-review-h1-2018-market-67

Table Of Content-

List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Tumor Necrosis Factor Receptor Superfamily Member 18 Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18 Overview 6
Tumor Necrosis Factor Receptor Superfamily Member 18 Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18 Therapeutics Development 7
Products under Development by Stage of Development 7
Products under Development by Therapy Area 8
Products under Development by Indication 9
Products under Development by Companies 10
Tumor Necrosis Factor Receptor Superfamily Member 18 Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18 Therapeutics Assessment 13
Assessment by Mechanism of Action 13
Assessment by Route of Administration 14
Assessment by Molecule Type 15
Tumor Necrosis Factor Receptor Superfamily Member 18 Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18 Companies Involved in Therapeutics Development 17
Ablynx NV 17
Apogenix AG 17
BristolMyers Squibb Co 17
Checkpoint Therapeutics Inc 18
GigaGen Inc 19
Incyte Corp 19
Leap Therapeutics Inc 20
MedImmune LLC 20
Merck & Co Inc 21
Novartis AG 21

Contact Us-

 New York City Zone 01,
 United States,
 Int’l: (+1) 646 781 7170,
 UK(Toll free): +44 800 088 5734,
 help@24marketreports.com

 

Link To Directory
Top Searches - Trending Searches - New Articles - Top Articles - Trending Articles - Featured Articles - Top Members

Copyright 2019 Uberant.com
581,646 total articles and counting.